Literature DB >> 16203464

Deaths in the first two weeks of maintenance treatment in NSW in 1994: identifying cases of iatrogenic methadone toxicity.

J R Caplehorn1.   

Abstract

A study was undertaken to estimate the frequency of iatrogenic methadone toxicity in the first 2 weeks of maintenance treatment in NSW. Cases were identified from a list of all 1994 methadone-associated deaths using data on methadone patients held by the NSW and Queensland Health Departments. The likely causes of death were determined from data collected from coronial files. A forensic toxicologist experienced in the area gave an independent opinion. Of the 14 deaths in the first 2 weeks of maintenance, at least 10 were primarily caused by the toxic effects of methadone prescribed by NSW doctors. The rate of fatal iatrogenic methadone toxicity was 2.2 per thousand admissions to maintenance. Victims of fatal iatrogenic toxicity often displayed signs of methadone intoxication in the days before their death. They invariably died several hours after taking the fatal dose, usually after seeming to go to sleep. Often friends or family were concerned about their welfare, were unable to rouse them from their "sleep" and frequently reported the deceased was "snoring" loudly for some time before their demise. The author recommends that patients entering methadone maintenance should be informed of the risks and should be required to give written consent to treatment. To prevent fatal methadone toxicity, patients should receive daily medical assessment during the first 1-2 weeks of maintenance.

Entities:  

Year:  1998        PMID: 16203464     DOI: 10.1080/09595239800187551

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  13 in total

1.  Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study.

Authors:  John Strang; Jim McCambridge; David Best; Tracy Beswick; Jenny Bearn; Sian Rees; Michael Gossop
Journal:  BMJ       Date:  2003-05-03

Review 2.  Methadone tolerance testing in drug misusers.

Authors:  Adam Bakker; Cindy Fazey
Journal:  BMJ       Date:  2006-11-18

3.  Intravenous methadone application as a serious risk factor for an overdose death: methadone-related fatalities in Hamburg from 2007 to 2012.

Authors:  Stefanie Iwersen-Bergmann; Hilke Jungen; Hilke Andresen-Streichert; Alexander Müller; Sally Elakkary; Klaus Püschel; Axel Heinemann
Journal:  Int J Legal Med       Date:  2014-05-25       Impact factor: 2.686

4.  Methadone use in a male with the FMRI premutation and FXTAS.

Authors:  Zukhrofi Muzar; Reymundo Lozano; Andrea Schneider; Patrick E Adams; Sultana M H Faradz; Flora Tassone; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2015-04-21       Impact factor: 2.802

Review 5.  Opioids for managing chronic non-malignant pain: safe and effective prescribing.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Angela Mailis-Gagnon; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

Review 6.  Pharmacotherapy of dual substance abuse and dependence.

Authors:  George A Kenna; Darci M Nielsen; Patricia Mello; Alison Schiesl; Robert M Swift
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.

Authors:  E Andrew Townsend; Bruce E Blough; David H Epstein; S Stevens Negus; Yavin Shaham; Matthew L Banks
Journal:  Neuropsychopharmacology       Date:  2022-07-29       Impact factor: 8.294

Review 8.  Methadone deaths: risk factors in pain and addicted populations.

Authors:  Vania Modesto-Lowe; Donna Brooks; Nancy Petry
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

9.  Determinants of overdose incidents among illicit opioid users in 5 Canadian cities.

Authors:  Benedikt Fischer; Suzanne Brissette; Serge Brochu; Julie Bruneau; Nady el-Guebaly; Lina Noël; Jürgen Rehm; Mark Tyndall; Cameron Wild; Phil Mun; Emma Haydon; Dolly Baliunas
Journal:  CMAJ       Date:  2004-08-03       Impact factor: 8.262

10.  Potential for Precision Medicine in Methadone Treatment of Opioid Use Disorder.

Authors:  Andrew J Saxon
Journal:  J Addict Med       Date:  2020 Sep/Oct       Impact factor: 4.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.